Amicus Therapeutics

Amicus Therapeutics, Inc.
Company type	Public
Traded as	Nasdaq: FOLD; Russell 2000 Component
Industry	Biotechnology
Founded	February 4, 2002
Headquarters	Philadelphia, Pennsylvania, United States
Key people	John Crowley (chairman emeritus); Bradley Campbell (president and COO); Daphne Quimi (CFO); David Clark (chief people officer);
Revenue	$91,245,000 (2018); $36,930,000 (2017);
Operating income	($328,777,000) (2018); ($441,985,000) (2017);
Net income	($349,089,000) (2018); ($449,121,000) (2017);
Total assets	$789,951,000 (2018); $627,024,000 (2017);
Total equity	$342,912,000 (2018); $352,850,000 (2017);
Number of employees	508 (31 Dec 2018)
Website	www.amicusrx.com
	Footnotes / references;

Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, PA. The company went public in 2007 under the NASDAQ trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.